

Note: This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



September 24, 2025

Company name: ZUIKO Corporation
Representative: Toyoshi Umebayashi, President & CEO
Listing: Tokyo Stock Exchange Prime Market
Securities code: 6279
Inquiries: Fumihiko Okuno, Director
Telephone: +81-72-648-2215

Notice Regarding Establishment of Second-tier Subsidiary by Consolidated Subsidiary

ZUIKO CORPORATION (the “Company”) announces that it has resolved, at Board of Directors held on today, ZUIKO (Shanghai) Corporation, a consolidated subsidiary of the Company, established a new subsidiary. The establishment of this subsidiary was discussed at the Board of Directors in June and August 2025, and preparations were underway after the outline of the establishment was approved. However, the Board of Directors passed a resolution at a new meeting after the details were finalized, resulting in post-approval. The new subsidiary becomes a specified subsidiary of the Company, given that the capital of the subsidiary is equivalent to more than 10/100 of the capital of the Company.

1. Background and objectives for establishment of the subsidiary

ZUIKO MEDICAL CORPORATION, the subsidiary of the Company, sells medical supplies such as wound dressing "Plus moist"(*) mainly to medical institutions, pharmacies and general consumers in Japan. So far, ZUIKO MEDICAL CORPORATION have sold its products to China through a local company as its exclusive distributor. However, we have reviewed our strategy and decided to establish our own sales company in Shanghai to handle Chinese market so that we can expand sales in China more aggressively.

In the Fourth Medium-Term Business Plan, which started in the fiscal year ending February 2026, the Company has set the goal of "expand our business portfolio by accelerating new businesses". We will develop sales channels for wound dressings in the Chinese medical supplies market, which is larger than Japan's, and aim to grow our new business.

(*) wound dressing

It is a medical device (medical material) used to cover wound.

“Plus moist” series have achieved high functionality through its unique technology, the result of extensive research into controlling the wound exudate, which is considered to be the most important factor in wound treatment.

2. Overview of the subsidiary

(1)	Name	ZUIKO (Shanghai) Med Health Corporation	
(2)	Location	Room A-906, No.188 Yesheng Road, China (Shanghai) Pilot Free Trade Zone	
(3)	Title and name of representative	Yi Xu, Chairman	
(4)	Description of business	Sales of medical equipment and supplies	
(5)	Share capital	50,000,000 CNY	
(6)	Date of establishment	August 28, 2025	
(7)	Major shareholders and ownership ratios	ZUIKO (Shanghai) Corporation: 100%	
(8)	Relationship between the Company and said company	Capital relationship	ZUIKO (Shanghai) Corporation holds 100% of shares.
		Personnel relationship	Director in ZUIKO (Shanghai) Corporation is appointed as a director in this subsidiary.
		Business relationship	ZUIKO MEDICAL CORPORATION will sell its products to this subsidiary.
		Related party relationship	Not applicable
(9)	Consolidated operating results and consolidated financial positions of said company for the last three years	Not applicable	

3. Future outlook

The impact on financial results for the fiscal year ending February 2026 is expected to be minimal. If any matters that should be disclosed arise in the future, they will be disclosed separately in a timely manner.